According to TipRanks, in a report released yesterday, Sachin Jain of Bank of America Securities maintained its “buy” rating on AstraZeneca. The company’s stock closed at 13,960.00 pence yesterday.
According to TipRanks data, Jain is a 4-star analyst with an average return rate of 4.5% and a success rate of 58.38%. Jain covers the healthcare sector, with a focus on tracking stocks such as AstraZeneca, Novartis, and GlaxoSmithKline.
AstraZeneca's current analysts unanimously rate it as a 'strong buy' with a consensus target price of 15,676.65 pence, representing a 12.30% upside from the current level. In another report released yesterday, Bernstein also maintained a 'buy' rating for the stock, with a target price of 198.00 pounds.
According to AstraZeneca's latest financial report for the quarter ending June 30, the company's revenue for that period was 15.29 billion pounds, with a net profit of 2.49 billion pounds. In comparison, the revenue for the same period last year was 14.84 billion pounds, and the net profit was 2.52 billion pounds.
Based on the trading activities of 15 company insiders recently, their sentiment towards this stock is generally positive. This indicates that, in the past quarter, there has been an increase in the number of insiders who have increased their holdings of AZN shares compared to earlier this year.
